FDA Panel To Vote On Hologic’s Permanent Birth Control Device Next Month
This article was originally published in The Gray Sheet
Executive Summary
Hologic's PMA for the Adiana permanent female birth control product will be considered by an FDA advisory panel Dec. 13, the agency said Nov. 8
You may also be interested in...
Hologic/Cytyc Merger Combines Diverse Women’s Health Device Portfolios
The combination of mammography device maker Hologic and cervical cancer test firm Cytyc will create a women's health powerhouse with $1.44 billion in combined annual revenues
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.